Incidence and predictive factors of depression among patients with HIV infection in Guadeloupe: 1988

Abstract

Summary

A retrospective cohort study was conducted to determine the incidence and the predictive factors of depression in a cohort of 2737 HIV/AIDS-infected patients in Guadeloupe followed for a total of 8402 patient-years. The incidence rate of first observed depression was 2.2 per 100 person-years (95% confidence interval [CI], 1.9–2.6). A single failure Cox proportional hazards model showed that the 1997–2000 inclusion period (hazard ratio [HR] = 1.60; 95% CI = 1.10–2.40; p = 0.01), the 2001–2009 inclusion period (HR = 1.50; 95% CI = 1.02–2.40; p = 0.04), the more advanced CDC stage (HR = 2.30; 95% CI = 1.30–3.10; p = 0.000) and the annual frequency of visits > 10 (HR = 2.30; 95% CI = 1.70–3.30; p = 0.000) were associated with an increased risk of depression. Incidence of depression in this HIV cohort was high and the hazard function showed three peaks of depression (2, 7 and 12 years). Physicians should be vigilant to psychological distress throughout life with HIV.

Keywords

HIV AIDS mood disorders Guadeloupe depression incidence predictive factors

Get full access to this article

View all access options for this article.

References

CAREC/PAHO/WHO. The Caribbean HIV/AIDS epidemic and the situation in member countries of the Caribbean Epidemiology Centre (CAREC) 2007. Available at: http://www.carpha.org/carec/index.php?option=com_docman&task=doc_download&gid=51&Itemid== (2007, accessed 24 November 2013).

Becker

Sanchez

Dew

. Neuropsychological abnormalities among HIV-infected individuals in a community-based sample. Neuropsychology 1997; 11: 592–601.

Penzak

Reddy

Grimsley

. Depression in patients with HIV infection. Am J Health Syst Pharm 2000; 57: 376–386; quiz 387–389.

Williams

Narciso

Browne

. The prevalence, correlates, and costs of depression in people living with HIV/AIDS in Ontario: implications for service directions. AIDS Educ Prev 2005; 17: 119–130.

Perkins

Stern

Golden

. Mood disorders in HIV infection: Prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry 1994; 151: 233–236.

Grant

. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008; 20: 33–47.

Kalichman

Rompa

Cage

. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIVAIDS. J Nerv Ment Dis 2000; 188: 662–670.

Gorman

Foley

Ettenhofer

. Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 2009; 19: 186–203.

Hinkin

Castellon

Durvasula

. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59: 1944–1950.

10.

Nacher

Adriouch

Godard Sebillotte

. Predictive factors and incidence of anxiety and depression in a cohort of HIV-positive patients in French Guiana. AIDS Care 2010; 22: 1086–1092.

11.

World Health Organization. CIM-10: Classification Statistique Internationale des Maladies et des Problèmes de Santé Connexes, Dixième Révision 1995; Vol. 2, Manuel d'Utilisation. Geneva: WHO.

12.

Dubé

Benton

Cruess

. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30: 237–246.

13.

Olley

Gxamza

Seedat

. Psychopathology and coping in recently diagnosed HIV/AIDS patients – the role of gender. S Afr Med J 2003; 93: 928–931.

14.

Judd

Komiti

Chua

. Nature of depression in patients with HIV/AIDS. Aust N Z J Psychiatry 2005; 39: 826–832.

15.

Silveira

Guttier

Pinheiro

. Depressive symptoms in HIV-infected patients treated with highly active antiretroviral therapy. Rev Bras Psiquiatr 2012; 34: 162–167.

16.

Bing

Burnam

Longshore

. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58: 721–728.

17.

Gibbie

Mijch

Ellen

. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med 2006; 7: 112–121.

18.

Bouhnik

Préau

Vincent

. MANIF 2000 Study Group. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10: 53–61.

19.

Ammassari

Antinori

Aloisi

. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45: 394–402.

20.

Barfod

Gerstoft

Rodkjaer

. Patient’s answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: a cross-sectional survey. AIDS Patient Care STD 2005; 19: 317–325.

21.

Blanco

JMS

Pérez

Lima

AOL

. Adherence to antiretroviral treatment in prisons. AIDS Res Hum Retroviruses 2005; 21: 683–688.

22.

Spire

Duran

Souville

. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481–1496.

23.

Pappin

Wouters

Booysen

. Anxiety and depression among patients enrolled in a public sector antiretroviral treatment programme in South Africa: a cross-sectional study. BMC Public Health 2012; 12: 244–244.

Incidence and predictive factors of depression among patients with HIV infection in Guadeloupe: 1988–2009

Abstract

Summary

Keywords

Get full access to this article

References